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occurred in 5 patients (1.8%). There were more female, adenocarci-
noma patients in N2 group (p<0.05); however, T stage was not different 
between N1 and N2 groups. The number of metastatic lymph nodes and 
nodal stations were 5.6 ± 5.6 and 2.5 ± 1.4 in N2 group, which were 
signiﬁcantly higher than 2.3 ± 1.7 and 1.2 ± 0.5 of N1 group (p<0.05). 
The overall 5-year survivals of N1 and N2 groups were 62.0% and 
39.6% (p<0.05). Multivariate analysis revealed that the age and the 
number of metastatic nodal stations were signiﬁcant risk factors for 
overall survival (p<0.05), however, N2 disease was not a signiﬁcant 
risk factor. The 5-year survival of patients with 1, 2, and 3 metastatic 
nodal stations were 68.4%, 32.3%, and 0% in N1 group, and 68.2%, 
32.0%, and 15.0% in N2 group, which did not show signiﬁcant differ-
ence between N1 and N2 groups.
Conclusions: In our study, multiplicity of metastatic nodal station 
signiﬁcantly affected overall survival in NSCLC with nodal metastasis 
rather than the locations of metastatic lymph node. Worse prognosis of 
N2 disease than N1 disease was due to the high probability of multiple 
metastatic nodal stations of N2 disease.
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Background: The 5-year survival rate after complete resection of non-
small cell lung cancer has improved with the decades from 41% in the 
1970’s, to 58% in the 1980’s, 63% in the 1990’s, to 78% since 2000. 
Factors related to the improvement were analyzed. 
Method: We used the survival index to ascertain how the 5-year sur-
vival rate of patients changed with the decade according to stage of the 
disease. The survival index was calculated by multiplying the propor-
tion of cases by the 5-year survival rate at each stage.
Results: The proportion of stage I cases was 54% in the 1970’s, and in-
creased to 64% in the 1980’s, 70% in the 1990’s, and 79% since 2000. 
The 5-year survival rate of stage I patients was 58% in the 1970’s, 
and increased to 71% in the 1980’s, 76% in the 1990’s, and 85% since 
2000. The survival index of stage I increased from 32 in the 1970’s, 
to 45 in the 1980’s, 53 in the 1990’s, and 67 since 2000. The stage I 
cases were then sub-classiﬁed in to stage IA and stage IB cases and the 
survival index of the stage IA cases increased from 18 in the 1970’s, 
to 29 in the 1980’s, 39 in the 1990’s, and 53 since 2000. The propor-
tion of stage IA cases detected by a lung cancer mass screening system 
increased from 17% in the 1970’s, to 28% in the 1980’s, 33% in the 
1990’s, and 37% since 2000.
Decade
survival 
rate(%)
Survival index (proportion of cases % × survival rate %)
p-I p-II p-III p-IV
1970-1979
(N=186)
41 32
(54×58)
7
(23×33)
2
(22×10)
0
(1×0)
1980-1989 58 45
(64×71)
8
(16×50%)
5
(20×25)
0
(1×0)(N=630)
1990-1999 63 53
(70×76)
5
(13×42)
5
(18×29)
0
(0×0)(N=1234)
2000-2005 78 67
(79×85)
7
(11×59)
4
(10×36)
0
(0×0)(N=1003)
Conclusion: As the lung cancer mass screening system has come into 
widespread use in Japan, the number of stage IA lung cancer cases 
that have been detected has increased, and because of that the surgical 
results have improved with decades.
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Objectives: To evaluate the compliance with adjuvant chemotherapy 
for completely resected non-small cell lung cancer (NSCLC).
Methods: Between January 2004 and May 2006, the patients with 
ECOG status 0 or 1 who underwent complete resection for NSCLC 
were referred to the oncologists for the adjuvant chemotherapy. Plati-
num-based adjuvant chemotherapy was performed with 3 or 4 cycles 
according to the protocol or the preference by oncologists. 
Results: Two hundred and thirty-two patients were enrolled in the pro-
spective data collection. Median age was 60.9 years and 76.7 % were 
male. Stage IB, II and III were 34.9%, 28.8% and 36.2%, respectively. 
Eleven patients (4.7%) completed one cycle, 8 (3.4%) completed two, 6 
(2.6%) completed three and 142 patients (61.2%) completed all planned 
cycles. Sixty ﬁve patients (28%) received no therapy. The causes of 
start failure for adjuvant chemotherapy consisted of decreased postop-
erative performance status (n=39), refusal such as ﬁnancial problems 
(n=13) and distant metastasis at initial follow up (n=2). The causes 
of cessation during adjuvant chemotherapy were composed of severe 
adverse effects (n=15), aggravation of disease with newly developed 
metastasis (n=4) and others (n=6). The mortality related to the adjuvant 
chemotherapy was 0.86%(n=2) due to pneumonia and sepsis.
Univariate analysis showed that age, postoperative complications and 
the in-hospital duration were the signiﬁcant factors for the completion 
of adjuvant chemotherapy. Preoperative pulmonary function, smoking 
history, surgical extent (lobectomy versus pneumonectomy) and video-
assisted thoracoscopic surgery were not signiﬁcant. Multivariate analy-
sis demonstrated statistically signiﬁcant differences in compliance with 
only age. Increasing age was associated with decreased compliance. 
Mean age was 59 years old in patients with completion of adjuvant 
chemotherapy compared with 64 years old in those who did not achieve 
the satisfactory chemotherapy. 
Conclusion: Adjuvant chemotherapy for completely resected non-
small cell lung cancer is performed with satisfactory compliance 
about 60%. Age plays an important role in the compliance of adjuvant 
chemotherapy. Elderly subsets will be examined to help determine the 
effect of age on compliance and outcome.
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Background: Somatic gain-of-function mutations in EGFR (exons 19 
and 21) and KRAS, (exon 2) are found in some lung adenocarcinomas. 
In patients with metastatic disease, these mutations have predictive and 
prognostic signiﬁcance: 1) EGFR mutations are associated with sensi-
tivity to the tyrosine kinase inhibitors, geﬁtinib and erlotinib, 2) KRAS 
mutations are associated with primary resistance to these drugs, and 3) 
patients with EGFR mutant tumors may have a longer overall survival 
(OS) versus patients with EGFR wildtype tumors. Whether EGFR and 
KRAS mutations also have an impact on survival, when compared to 
one another, in patients who undergo lung resection for curative intent 
in the absence of targeted therapy has not been established.
Methods: We analyzed the clinical characteristics and outcomes data 
for 300 patients who underwent resection at our institution for Stage 
I-III lung adenocarcinoma. Tumors from all patients were assessed for 
both EGFR and KRAS mutations by direct dideoxynucleotide sequenc-
ing by the Genome Sequencing Center at Washington University St. 
Louis, and/or PCR based methods at Memorial Sloan-Kettering Cancer 
Center. Survival distributions were estimated using Kaplan-Meier 
curves and compared using the log-rank test. 
Results: We found EGFR and KRAS mutations in tumors from 40 and 
50 patients, respectively. No tumor had both mutations. None of the 
patients with mutations received induction or adjuvant therapy with 
erlotinib or geﬁtinib. With a median time to follow-up of 22.3 months, 
patients with EGFR mutant tumors had a longer overall survival on 
univariate analysis versus patients with KRAS mutant tumors (p=0.015, 
see Figure 1) and a trend towards longer survival versus patients with 
tumors wildtype for both genes (p=.070). After adjustment for patho-
logic stage, patients with EGFR mutations displayed a trend towards 
longer survival when compared to patients with KRAS mutations 
(p=0.166). The median OS for patients with EGFR mutant or wildtype 
tumors was not reached, while for the patients with KRAS 
Conclusions: In the absence of treatment with EGFR-targeted therapy, 
EGFR and KRAS mutations are positive and negative molecular predic-
tors, respectively, of survival in resected lung adenocarcinoma. These 
data suggest further that EGFR and KRAS mutations deﬁne clinically 
distinct molecular subsets of lung adenocarcinoma. Mutational status 
should be routinely performed on resected specimens, and EGFR and 
KRAS mutations should be considered as prognostic factors in studies 
of adjuvant therapy.
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Background: NSCLC is one of the leading causes of cancer-related 
deaths; however, a substantial number of patients with early stage dis-
ease will survive after treatment. No comprehensive clinical programs 
designed for NSCLC survivors exist and few studies examine the clini-
cal characteristics and quality of life in NSCLC survivors. 
Methods: A novel thoracic cancer survivorship program (TCSP) 
utilizing a nurse practitioner (NP) care model was developed at a single 
institution. Eligible patients include those with history of Stage I/II 
NSCLC, 1 year after surgical resection without evidence of disease. 
Cancer surveillance and post-treatment evaluation are performed by 
the NP with history and physical examination and a contrast-enhanced 
chest CT scan biannually for the second post-operative year and an-
nually thereafter. Patient demographics, clinical characteristics, QOL 
assessment and cancer screening compliance data are collected in a 
prospective thoracic survivorship database. Retrospective review to 
examine baseline clinical characteristics and QOL was performed.
Results: A total of 223 patients with NSCLC were seen in the TCSP 
from January, 2006 through February, 2007. The mean age was 71 
years (range 48-91). Fifty-eight percent (n=129) were female. Eighty-
ﬁve percent (n=191) of patients were diagnosed with Stage I NSCLC, 
and 87% (n=195) were treated with surgery alone. A small number of 
patients received either induction (n=14, 6%) or adjuvant treatment 
(n=14, 6%) with either chemotherapy, radiation therapy, or both. Dis-
ease-free interval ranged from 1-18 years. Eighty-one percent (n=181) 
of patients identiﬁed themselves as former tobacco smokers, with only 
5% (n=11) reporting current tobacco use. Using a 0-10 numeric rating 
scale (NRS) to report average level of pain and fatigue, 155 patients re-
ported a mean fatigue score of 4.1 with 47% (n=73) rating their fatigue 
level 5 or higher. The mean pain score for 154 patients was 2.2 with 
21% (n=33) rating their pain level 5 or higher. Anxiety and depression 
were measured by self report in 83 patients. One-third (n=28) reported 
anxiety and 17% (n=14) reported depression triggering a referral 
for psychosocial support. Seventy-four percent of patients (n=166) 
reported having some method of colorectal cancer (CRC) screening 
performed. Eighty-eight percent (114/129) of females reported breast 
cancer screening with mammography and 50% of these (57/114) 
reported mammogram within the last year. Cervical cancer screening 
by Papanicolaou smear (PAP) was reported by 64% of women (82/129) 
with 39% of these women (32/82) having a PAP test within the last 
year. Eighty percent (75/94) of males reported undergoing prostate 
speciﬁc antigen (PSA) testing; 67% (50/75) of these men having PSA 
testing within the past 1 year.
Conclusions: The initial observations of this novel thoracic survivor-
ship program show that a substantial percentage of NSCLC survivors 
report elevated levels of pain, fatigue, anxiety and depression post-
treatment. In addition, adherence to recommended cancer screening 
tests is highly variable. Based on this, interventions to address the 
needs of NSCLC survivors are warranted.
